Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression-Reference-Cited by-同舟云学术

Oncogenic Forms of p53 Inhibit p53-Regulated Gene Expression

Published:1992-05-08 Issue:5058 Volume:256 Page:827-830
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Kern Scott E.¹,Pietenpol Jennifer A.¹,Thiagalingam Sam¹,Seymour Albert¹,Kinzler Kenneth W.¹,Vogelstein Bert¹

Affiliation:

1. Oncology Center and Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21231.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference49 articles.

1. Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas

2. Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53

3. BARGONETTI, J, WILD-TYPE BUT NOT MUTANT P53 IMMUNOPURIFIED PROTEINS BIND TO SEQUENCES ADJACENT TO THE SV40 ORIGIN OF REPLICATION, CELL 65: 1083 (1991).

4. BARTEK, J, GENETIC AND IMMUNOCHEMICAL ANALYSIS OF MUTANT P53 IN HUMAN BREAST-CANCER CELL-LINES, ONCOGENE 5: 893 (1990).

5. BUCHMAN, A.R., CONNECTIONS BETWEEN TRANSCRIPTIONAL ACTIVATORS, SILENCERS, AND TELOMERES AS REVEALED BY FUNCTIONAL-ANALYSIS OF A YEAST DNA-BINDING PROTEIN, MOLECULAR AND CELLULAR BIOLOGY 8: 5086 (1988).

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules;2024-07-27

2. The Abl1 tyrosine kinase is a key player in doxorubicin-induced cardiomyopathy and its p53/p73 cell death mediated signaling differs in atrial and ventricular cardiomyocytes;2024-07-10

3. Significant value of p53 accumulated in Invasive Ductal Breast Carcinoma;2024-03-06

4. Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy;Cancer Communications;2024-02-04

5. The Abl1 Tyrosine Kinase and p53 are Key Players in Doxorubicin-Induced Cardiomyopathy and Their Cell Death Signaling Differs in Atrial and Ventricular Cardiomyocytes;2024